Sodium phosphate, monobasic

Identification

Name

Sodium phosphate, monobasic

Accession Number

DB09449  (DB09127, DB11083, DB09524, DB09542, DB09468, DB11084, DB09482, DB09469, DB09525, DBSALT001969)

Type

Small Molecule

Groups

Approved

Description

Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Sodium phosphate, monobasic (DB09449)

×

Close

Synonyms

• Disodium hydrogen phosphate anhydrous
• Monosodium dihydrogen monophosphate
• Monosodium dihydrogen orthophosphate
• Monosodium monophosphate
• Monosodium phosphate, anhydrous
• Phosphoric acid, monosodium salt, anhydrous
• Sodium acid phosphate
• Sodium biphosphate, anhydrous
• Sodium dihydrogen phosphate, anhydrous
• Sodium orthophosphate
• Sodium orthophosphate monobasic
• Sodium phosphate monobasic
• Sodium phosphate monobasic (anhydrate)
• Sodium phosphate monobasic (anhydrous)
• Sodium phosphate, monobasic
• Sodium phosphate, monobasic anhydrous
• Sodium phosphate,monobasic
• Sodium primary phosphate

External IDs

E-339(I) / INS NO.339(I) / INS-339(I)

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Sodium phosphate, monobasic, dihydrate	5QWK665956	13472-35-0	VBJGJHBYWREJQD-UHFFFAOYSA-M
Sodium phosphate, monobasic, monohydrate	593YOG76RN	10049-21-5	BBMHARZCALWXSL-UHFFFAOYSA-M

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Phosphoric acid	unknown	E4GA8884NN	7664-38-2	NBIIXXVUZAFLBC-UHFFFAOYSA-N
Sodium cation	ionic	LYR4M0NH37	17341-25-2	FKNQFGJONOIPTF-UHFFFAOYSA-N
Phosphate ion	ionic	NK08V8K8HR	14265-44-2	NBIIXXVUZAFLBC-UHFFFAOYSA-K

Product Images

PreviousNext

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Additive Formula 3	Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL)	Solution	Intravenous	Terumo Bct, Ltd	2002-05-29	Not applicable
Additive Formula 3	Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL)	Solution	Intravenous	Terumo Bct, Ltd	2002-05-29	Not applicable
Additive Formula 3	Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL)	Solution	Intravenous	Terumo Bct, Ltd	2002-05-29	Not applicable
Additive Solution Formula 3 As-3	Sodium phosphate, monobasic, monohydrate (0.276 g) + Adenine (0.030 g) + Citric acid monohydrate (0.042 g) + Dextrose, unspecified form (1.10 g) + Sodium chloride (0.410 g) + Sodium citrate dihydrate (0.588 g)	Solution	Unknown	Terumo Bct, Inc.	2013-05-31	Not applicable
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)	Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)		Intravenous	Fenwal, Inc.	2007-03-01	Not applicable
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)	Sodium phosphate, monobasic, monohydrate (140 mg/63mL) + Adenine (27 mg/100mL) + Citric acid (188 mg/63mL) + D-glucose monohydrate (1.61 g/63mL) + D-glucose monohydrate (2.2 g/100mL) + Mannitol (750 mg/100mL) + Sodium chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL)		Intravenous	Fenwal, Inc.	2010-06-21	Not applicable
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)	Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)		Intravenous	Fenwal, Inc.	2007-03-01	Not applicable
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)	Sodium phosphate, monobasic, monohydrate (140 mg/63mL) + Adenine (27 mg/100mL) + Citric acid (188 mg/63mL) + D-glucose monohydrate (1.61 g/63mL) + D-glucose monohydrate (2.2 g/100mL) + Mannitol (750 mg/100mL) + Sodium chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL)		Intravenous	Fenwal, Inc.	2007-03-01	Not applicable
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)	Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)	Kit	Intravenous	Fenwal, Inc.	2007-10-01	Not applicable
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)	Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)		Intravenous	Fenwal, Inc.	2007-06-06	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Azuphen Mb	Sodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (120 mg/1) + Methylene blue trihydrate (10 mg/1) + Phenyl salicylate (36 mg/1)	Capsule	Oral	Burel Pharmaceuticals, Llc	2015-09-28	2016-11-01
Darpaz	Sodium phosphate, monobasic (40.8 mg/1) + Hyoscyamine sulfate dihydrate (.12 mg/1) + Methenamine (81 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (32.4 mg/1)	Tablet	Oral	River's Edge Pharmaceuticals, LLC	2008-12-01	2011-05-31
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate	Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)	Tablet	Oral	Cardinal Health	2012-06-28	2018-05-17
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate	Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)	Tablet	Oral	Avera McKennan Hospital	2015-03-11	2018-06-05
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate	Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)	Tablet	Oral	American Health Packaging	2014-05-13	2020-06-30
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate	Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)	Tablet	Oral	Carilion Materials Management	2012-06-28	Not applicable
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate	Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)	Tablet	Oral	Kaiser Foundations Hospitals	2014-07-07	Not applicable
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate	Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)	Tablet	Oral	Rising Pharmaceuticals, Inc.	2012-06-28	Not applicable
Hyolev Mb	Sodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (32.4 mg/1)	Tablet	Oral	Burel Pharmaceuticals, Llc	2015-06-26	2016-11-01
Indiomin Mb	Sodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (120 mg/1) + Methylene blue trihydrate (10 mg/1)	Capsule	Oral	Burel Pharmaceuticals, Llc	2015-09-28	2016-10-24

Categories

• Acids
• Acids, Noncarboxylic
• Agents that reduce seizure threshold
• Anions
• Electrolytes
• Ions
• Laxatives
• Osmotic Laxatives
• Phosphate salts
• Phosphoric Acids
• Phosphorus Acids
• Phosphorus Compounds
• Potassium Salt
• Urinary Acidifying Agents

UNII

KH7I04HPUU

CAS number

7558-80-7

Weight

Average: 119.977
Monoisotopic: 119.958839739

Chemical Formula

H₂NaO₄P

InChI Key

AJPJDKMHJJGVTQ-UHFFFAOYSA-M

InChI

InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1

IUPAC Name

sodium dihydrogen phosphate

SMILES

[Na+].OP(O)([O-])=O

Pharmacology

Indication

Used to treat constipation or to clean the bowel before a colonoscopy ^Label.

Associated Conditions

• Acid-Base Imbalance
• Acidosis
• Dehydration
• Diarrhea
• Drug Poisoning
• Electrolyte imbalance
• Hypophosphatemia
• Minor burns

Associated Therapies

• Bowel preparation therapy
• Continuous Renal Replacement Therapy
• Fluid replacement
• Parenteral rehydration therapy
• Total parenteral nutrition therapy
• Fluid and electrolyte maintenance
• Irrigation of the ocular surface therapy
• Red blood cell rejuvination

Pharmacodynamics

Sodium phosphate inceases fecal water content to increase mobility through the large intestine ¹.

Mechanism of action

Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen ¹.

Unlock Additional Data

Additional Data Available

Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more

Additional Data Available

Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more

Additional Data Available

Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Absorption

Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h ³.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats ⁷. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma ⁴. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients ³.

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• All Drugs
• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental

Drug	Interaction
Unlock Additional Data
2,5-Dimethoxy-4-ethylamphetamine	The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.
2,5-Dimethoxy-4-ethylthioamphetamine	The serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.
4-Bromo-2,5-dimethoxyamphetamine	The serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.
7-Nitroindazole	The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Sodium phosphate, monobasic.
Acebutolol	Sodium phosphate, monobasic may increase the hyperkalemic activities of Acebutolol.
Aceclofenac	The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Aceclofenac.
Acemetacin	The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acemetacin.
Acetazolamide	Acetazolamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.
Acetylsalicylic acid	The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acetylsalicylic acid.
Aclidinium	The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aclidinium.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

Not Available

References

General References

1. Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [PubMed:17652123]
2. Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [PubMed:18645612]
3. Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [PubMed:19298584]
4. Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [PubMed:20958267]
5. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
6. FDA Guide: Sodium Phosphate Tablet [Link]
7. ChemIDPlus: Sodium Phosphate [Link]

External Links

PubChem Compound

23672064

PubChem Substance

347827853

ChemSpider

22626

ChEBI

37585

ChEMBL

CHEMBL1368

Wikipedia

Sodium_phosphates

FDA label

Download (359 KB)

MSDS

Download (84.7 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Completed	Not Available	Colonoscopy	1
3	Recruiting	Treatment	Bowel preparation therapy	1
3	Unknown Status	Not Available	Malignant Neoplasm of Colon	1
4	Completed	Not Available	Dry Eye	1
4	Completed	Other	Sickle Cell Disorders	1
4	Completed	Treatment	Colon Cleansing	1
4	Completed	Treatment	OSAS (Obstructive Sleep Apneas Syndrome) / Psoriasis	1
4	Not Yet Recruiting	Basic Science	Heart Defects,Congenital	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Solution	Unknown
Liquid	Intravenous
Kit	Intravenous
Solution	Intravenous
Paste	Dental
Injection	Intrathecal
Liquid	Irrigation
Liquid	Intravesical
Injection, solution	Intravenous
Tablet, coated	Oral
Tablet	Oral
Capsule	Oral
Liquid	Oral
Solution	Oral
Solution	Extracorporeal
Enema	Rectal
Solution	Respiratory (inhalation)
Tablet, film coated	Oral
Tablet, sugar coated	Oral

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
Unlock Additional Data
US7687075	No	2010-03-30	2028-06-22
US7084130	No	2006-08-01	2021-11-29

Additional Data Available

Filed On
Filed On
The date on which a patent was filed with the relevant government.
Learn more

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	Decomposes at 75	MSDS
water solubility	121 g/L	MSDS

Predicted Properties

Property	Value	Source
logP	-1	ChemAxon
pKa (Strongest Acidic)	1.8	ChemAxon
Physiological Charge	-2	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	80.59 Å2	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	13.53 m3·mol-1	ChemAxon
Polarizability	5.53 Å3	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available

Taxonomy

Description

This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.

Kingdom

Inorganic compounds

Super Class

Mixed metal/non-metal compounds

Class

Alkali metal oxoanionic compounds

Sub Class

Alkali metal phosphates

Direct Parent

Alkali metal phosphates

Alternative Parents

Inorganic sodium salts / Inorganic oxides

Substituents

Alkali metal phosphate / Inorganic sodium salt / Inorganic oxide / Inorganic salt

Molecular Framework

Not Available

External Descriptors

sodium phosphate (CHEBI:37585)

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on November 30, 2015 12:10 / Updated on March 01, 2020 23:44